206 related articles for article (PubMed ID: 21252093)
1. Sézary syndrome cells overexpress syndecan-4 bearing distinct heparan sulfate moieties that suppress T-cell activation by binding DC-HIL and trapping TGF-beta on the cell surface.
Chung JS; Shiue LH; Duvic M; Pandya A; Cruz PD; Ariizumi K
Blood; 2011 Mar; 117(12):3382-90. PubMed ID: 21252093
[TBL] [Abstract][Full Text] [Related]
2. Syndecan-4 mediates the coinhibitory function of DC-HIL on T cell activation.
Chung JS; Dougherty I; Cruz PD; Ariizumi K
J Immunol; 2007 Nov; 179(9):5778-84. PubMed ID: 17947650
[TBL] [Abstract][Full Text] [Related]
3. The DC-HIL/syndecan-4 pathway inhibits human allogeneic T-cell responses.
Chung JS; Bonkobara M; Tomihari M; Cruz PD; Ariizumi K
Eur J Immunol; 2009 Apr; 39(4):965-74. PubMed ID: 19350579
[TBL] [Abstract][Full Text] [Related]
4. Depleting syndecan-4+ T lymphocytes using toxin-bearing dendritic cell-associated heparan sulfate proteoglycan-dependent integrin ligand: a new opportunity for treating activated T cell-driven disease.
Akiyoshi H; Chung JS; Tomihari M; Cruz PD; Ariizumi K
J Immunol; 2010 Apr; 184(7):3554-61. PubMed ID: 20176742
[TBL] [Abstract][Full Text] [Related]
5. The DC-HIL/syndecan-4 pathway regulates autoimmune responses through myeloid-derived suppressor cells.
Chung JS; Tamura K; Akiyoshi H; Cruz PD; Ariizumi K
J Immunol; 2014 Mar; 192(6):2576-84. PubMed ID: 24516197
[TBL] [Abstract][Full Text] [Related]
6. Binding of DC-HIL to dermatophytic fungi induces tyrosine phosphorylation and potentiates antigen presenting cell function.
Chung JS; Yudate T; Tomihari M; Akiyoshi H; Cruz PD; Ariizumi K
J Immunol; 2009 Oct; 183(8):5190-8. PubMed ID: 19794069
[TBL] [Abstract][Full Text] [Related]
7. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
[TBL] [Abstract][Full Text] [Related]
8. DC-HIL is a negative regulator of T lymphocyte activation.
Chung JS; Sato K; Dougherty II; Cruz PD; Ariizumi K
Blood; 2007 May; 109(10):4320-7. PubMed ID: 17284525
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of T-cell activation by syndecan-4 is mediated by CD148 through protein tyrosine phosphatase activity.
Chung JS; Cruz PD; Ariizumi K
Eur J Immunol; 2011 Jun; 41(6):1794-9. PubMed ID: 21469128
[TBL] [Abstract][Full Text] [Related]
10. DC-HIL/glycoprotein Nmb promotes growth of melanoma in mice by inhibiting the activation of tumor-reactive T cells.
Tomihari M; Chung JS; Akiyoshi H; Cruz PD; Ariizumi K
Cancer Res; 2010 Jul; 70(14):5778-87. PubMed ID: 20570888
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous T-cell lymphoma: malignant proliferation of T-regulatory cells.
Berger CL; Tigelaar R; Cohen J; Mariwalla K; Trinh J; Wang N; Edelson RL
Blood; 2005 Feb; 105(4):1640-7. PubMed ID: 15514008
[TBL] [Abstract][Full Text] [Related]
12. Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.
Zhang C; Li B; Gaikwad AS; Haridas V; Xu Z; Gutterman JU; Duvic M
J Invest Dermatol; 2008 Nov; 128(11):2728-2735. PubMed ID: 18496567
[TBL] [Abstract][Full Text] [Related]
13. The expression of cell adhesion molecule 1 and its splicing variants in Sézary cells and cell lines from cutaneous T-cell lymphoma.
Yamaguchi M; Morizane S; Hamada T; Miyake T; Sugaya M; Iwata H; Fujii K; Haramoto-Shiratsuki R; Nakagawa Y; Miura M; Ohshima K; Morishita K; Takahashi T; Imada M; Okada K; Uehara J; Sowa-Osako J; Iwatsuki K
J Dermatol; 2019 Nov; 46(11):967-977. PubMed ID: 31515833
[TBL] [Abstract][Full Text] [Related]
14. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.
Ni X; Zhang C; Talpur R; Duvic M
J Invest Dermatol; 2005 Apr; 124(4):741-50. PubMed ID: 15816832
[TBL] [Abstract][Full Text] [Related]
15. DC-HIL-expressing myelomonocytic cells are critical promoters of melanoma growth.
Chung JS; Tamura K; Cruz PD; Ariizumi K
J Invest Dermatol; 2014 Nov; 134(11):2784-2794. PubMed ID: 24936834
[TBL] [Abstract][Full Text] [Related]
16. The DC-HIL ligand syndecan-4 is a negative regulator of T-cell allo-reactivity responsible for graft-versus-host disease.
Chung JS; Tomihari M; Tamura K; Kojima T; Cruz PD; Ariizumi K
Immunology; 2013 Feb; 138(2):173-82. PubMed ID: 23113638
[TBL] [Abstract][Full Text] [Related]
17. Identification of cell surface molecules characterizing human cutaneous T-cell lymphomas.
Nikolova M; Bagot M; Boumsell L; Bensussan A
Leuk Lymphoma; 2002 Apr; 43(4):741-6. PubMed ID: 12153159
[TBL] [Abstract][Full Text] [Related]
18. Loss of receptors for transforming growth factor beta in human T-cell malignancies.
Kadin ME; Cavaille-Coll MW; Gertz R; Massagué J; Cheifetz S; George D
Proc Natl Acad Sci U S A; 1994 Jun; 91(13):6002-6. PubMed ID: 8016105
[TBL] [Abstract][Full Text] [Related]
19. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
20. Sézary Syndrome: Clinical and Biological Aspects.
Kohnken R; Fabbro S; Hastings J; Porcu P; Mishra A
Curr Hematol Malig Rep; 2016 Dec; 11(6):468-479. PubMed ID: 27704468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
